Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 49 recruiting now early-phase tilt #125 of 28,707 conditions

Autism: early-phase trial registry

49 of 105 indexed Autism trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #125 of 28,707 conditions by registered trial count.

105 US clinical trials · 49 currently recruiting · #125 of 28,707 conditions by registered trial count

Autism: 105 US clinical trials tracked, 49 recruiting.

Autism is the subject of 105 registered US clinical trials on ClinicalTrials.gov, 49 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 26 in Phase 1-2 (earlier-stage). The most active sponsor is Stanford University, running 16 of these trials.

Enrollment posture brief

Registry condition autism

OPEN 49 | RECR 47% | LATE 8 | EARLY 26 | RANK #125 | SPON 16

Nearest open-share peer: Bipolar II Disorder (47% recruiting · 15 trials)

Autism (this)47%Cognitive Impairment43.4%Migraine38.1%Hematopoietic and Lymphoid C33.3%Schizoaffective Disorder29.5%
Open-enrollment share among volume-matched conditions near Autism

Autism lists 49 open slots (47% of 105 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Autism on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Autism is recruiting above its size-band peers.

    49 of 105 indexed trials (46.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Autism research.

    Stanford University accounts for 16 of 105 trials (15.2%). 66 distinct sponsors appear on at least one study for this condition label.

  3. Most Autism trials plan to enrol fewer than 100 people.

    Median target enrolment is 60 among the 105 trials that report a genuine target (sentinel values excluded). 64 of those (61%) plan for fewer than 100 participants.

  4. Autism research is mostly interventional.

    92 interventional and 13 observational studies make up this index (87.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 223Phase 35Phase 43

Open and recent trials

105 total, page 2 of 3

ACTIVE NOT RECRUITING 297 participants

Mitochondrial Dysfunction in Autism Spectrum Disorder

University of Arkansas

NCT02000284

ACTIVE NOT RECRUITING 240 participants

Genetic Contributions to Autism Spectrum Disorders

Boston Children's Hospital

NCT01160783

ACTIVE NOT RECRUITING NA 200 participants

Project AFECT (Autism Family Empowerment Coaching and Training Program)

Stanford University

NCT05910502

ACTIVE NOT RECRUITING NA 132 participants

Developing Treatment, Treatment Validation and Treatment Scope in the Setting of an Autism Clinical Trial

Rutgers, The State University of New Jersey

NCT01260961

ACTIVE NOT RECRUITING NA 75 participants

A Center Based Study of Pivotal Response Treatment for Preschoolers With Autism

Stanford University

NCT03778827

ACTIVE NOT RECRUITING Phase 2 48 participants

Sulforaphane in a New Jersey (NJ) Population of Individuals With Autism

Rutgers, The State University of New Jersey

NCT02677051

ACTIVE NOT RECRUITING Phase 2 42 participants

Trial of Cannabidiol to Treat Severe Behavior Problems in Children With Autism

University of California, San Diego

NCT04517799

ACTIVE NOT RECRUITING NA 40 participants

The Effectiveness of an Autistic-delivered Peer-support Intervention for Autistic Adults: Community Autism Peer Specialist (CAPS) Program

Drexel University

NCT05702658

ACTIVE NOT RECRUITING Phase 2 40 participants

Pilot Trial of Pregnenolone in Autism

Stanford University

NCT02627508

ACTIVE NOT RECRUITING NA 24 participants

Theta Burst Stimulation for Refractory Depression in Autism Spectrum Disorder

Children's Hospital Medical Center, Cincinnati

NCT06670040

ACTIVE NOT RECRUITING NA 15 participants

Adapting BA for Minimally Verbal Autistic Adults

Rutgers, The State University of New Jersey

NCT06064422

COMPLETED Phase 3 702 participants

Pediatric Open-Label Extension Study

Sumitomo Pharma America

NCT01914393

COMPLETED NA 541 participants

A Lead-in Study Evaluating Efficacy of GuessWhat Mobile App Therapy for Children With Autism

Stanford University

NCT04739982

COMPLETED Phase 2 479 participants

Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine

Forest Laboratories

NCT01592747

COMPLETED 324 participants

Predictors of Caregiver Adaptation to Pervasive Developmental Disorders

National Human Genome Research Institute (NHGRI)

NCT00496210

COMPLETED 322 participants

Exome Sequencing in Autistic Spectrum Disorder

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NCT01059201

COMPLETED NA 250 participants

Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools

Health Resources and Services Administration (HRSA)

NCT01724047

COMPLETED NA 214 participants

Psychotherapy for Anxiety in Children With Autism Spectrum Disorder

University of South Florida

NCT02028247

COMPLETED NA 192 participants

Adaptive Interventions for Minimally Verbal Children With ASD in the Community

University of California, Los Angeles

NCT01751698

COMPLETED Phase 3 182 participants

A Trial of CM-AT in Children With Autism

Curemark

NCT00881452

COMPLETED Phase 2 180 participants

Cord Blood Infusion for Children With Autism Spectrum Disorder

Joanne Kurtzberg, MD

NCT02847182

COMPLETED Phase 2 137 participants

hCT-MSC in Children With Autism Spectrum Disorder

Joanne Kurtzberg, MD

NCT04089579

COMPLETED NA 118 participants

Intensive Intervention for Toddlers With Autism (EARLY STEPS)

University of California, Davis

NCT00698997

COMPLETED NA 112 participants

Randomized Controlled Trial of the P.L.A.Y. (Play and Language for Autistic Youngsters) Project Intervention for Autism

Richard Solomon MD

NCT01768806

COMPLETED Phase 2 102 participants

Open-label Study of Safety and Tolerability of Memantine in Children With Autism

Forest Laboratories

NCT01999894

COMPLETED Phase 4 96 participants

A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

NCT00576732

COMPLETED 83 participants

Show Me to Help Me

Akron Children's Hospital

NCT01311596

COMPLETED 77 participants

Study of Toddlers With Language Delay

National Institute of Mental Health (NIMH)

NCT01339767

COMPLETED NA 64 participants

Examination of Differential Valuation of Leisure Items and Attention as Reinforcers in Children With Autism

Emory University

NCT03152383

COMPLETED Phase 1 60 participants

An Autism Study Using Nambudripad's Food Allergy Elimination Treatments

Nambudripad's Allergy Research Foundation

NCT00247156

COMPLETED Phase 2 58 participants

A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder

Yamo Pharmaceuticals

NCT05067582

COMPLETED NA 48 participants

Adapting an Advocacy Services Intervention for Latinx Families of Transition-aged Youth With Autism Spectrum Disorder

Vanderbilt University

NCT06207149

COMPLETED NA 45 participants

Randomized Study of Fluoxetine in Children and Adolescents With Autism

Icahn School of Medicine at Mount Sinai

NCT00004486

COMPLETED Phase 2 45 participants

Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders

University of South Florida

NCT01178385

COMPLETED NA 44 participants

Services to Enhance Social Functioning in Adults With Autism Spectrum Disorders

University of Pennsylvania

NCT04788537

COMPLETED Phase 2 44 participants

Sulforaphane-rich Broccoli Sprout Extract for Autism

Andrew Zimmerman

NCT01474993

COMPLETED NA 44 participants

Social Cognition and Interaction Training for Autism

University of North Carolina, Chapel Hill

NCT02382172

COMPLETED Phase 2 41 participants

Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels Of Repetitive Behavior

University of California, Los Angeles

NCT01171937

COMPLETED NA 38 participants

Transcranial Photobiomodulation Therapy for the Treatment of Autistic Traits in Children and Adolescents With ADHD

Massachusetts General Hospital

NCT04569058

COMPLETED Phase 2 30 participants

Autologous Cord Blood Stem Cells for Autism

Sutter Health

NCT01638819

COMPLETED Phase 2 27 participants

Divalproex Sodium vs. Placebo in Childhood/Adolescent Autism

Montefiore Medical Center

NCT00211757

COMPLETED Phase 3 25 participants

Study of Paliperidone ER in Adolescents and Young Adults With Autism

Indiana University School of Medicine

NCT00549562

COMPLETED Phase 2 24 participants

Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children

The University of Texas Health Science Center, Houston

NCT00178503

COMPLETED 20 participants

MENTIS Personal Health Record Rapid Pilot Research Deployment and Evaluation

Northeastern University

NCT02090491

COMPLETED 17 participants

In Vivo Imaging of Therapeutic Electric Current Flow

University of Florida

NCT02453763

COMPLETED NA 17 participants

Coaching Children With Anxiety and Autism Through Telehealth

Medical University of South Carolina

NCT05588570

COMPLETED Phase 3 16 participants

A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms

University of Oklahoma

NCT00541346

COMPLETED NA 16 participants

Effect of Parenting With Positive Interven on Comm Inclusion for Military Connected and Dependents With Autism

Virginia Commonwealth University

NCT05580432

COMPLETED Phase 2 14 participants

Testing a Novel Speech Intervention in Minimally Verbal Children With Autism Spectrum Disorder (ASD)

Beth Israel Deaconess Medical Center

NCT03015272

COMPLETED Phase 2 14 participants

An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders

Cambridge Health Alliance

NCT00308074

← Previous Page 2 of 3 Next →

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 23
Phase 3 5
Phase 4 3

Named interventions

Most-linked intervention names on Autism records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
11 trials
Treatment as Usual Behavioral
3 trials
Aripiprazole Drug
2 trials
CM-AT Drug
2 trials
Placebo Biological
2 trials
Transcranial direct current stimulation Device
2 trials
Cord Tissue Mesenchymal Stromal Cells Biological
1 trials
Icons Other
1 trials

US sites by state

Facility locations filed on Autism trials. A trial with sites in several states counts in each.

California 35 trials
New York 12 trials
Pennsylvania 10 trials
New Jersey 10 trials
Florida 10 trials
Ohio 9 trials
Massachusetts 9 trials
Texas 8 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Autism page

105 registered trials, 49 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Autism condition card totals 105 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.